TESARO Company Profile (NASDAQ:TSRO)


TESARO logoTESARO, Inc. is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform. Rolapitant is a potent and long-acting neurokinin-1 receptor antagonist for the prevention of chemotherapy induced nausea and vomiting. Niraparib is an orally active and potent poly (adenosine diphosphate (ADP)-ribose) polymerase inhibitor. It has various ongoing clinical trials evaluating niraparib for the treatment of ovarian or breast cancers. It has initiated a Phase I, dose escalation study for its first immuno-oncology antibody, TSR-042, which targets Programmed cell death protein 1. It has commenced pre-clinical research for its antibody candidate targeting Lymphocyte-activation gene-3 andTSR-033. It has commenced a Phase I clinical trial of TSR-042.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:TSRO
  • CUSIP: 88156910
  • Web: www.tesarobio.com
  • Market Cap: $7 billion
  • Outstanding Shares: 53,864,000
Average Prices:
  • 50 Day Moving Avg: $139.02
  • 200 Day Moving Avg: $151.61
  • 52 Week Range: $83.26 - $192.94
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -28.73
  • P/E Growth: -0.60
Sales & Book Value:
  • Annual Revenue: $47.6 million
  • Price / Sales: 146.96
  • Book Value: $9.54 per share
  • Price / Book: 13.61
  • EBIDTA: ($398,820,000.00)
  • Net Margins: -910.35%
  • Return on Equity: -96.49%
  • Return on Assets: -65.48%
  • Debt-to-Equity Ratio: 0.26%
  • Current Ratio: 6.58%
  • Quick Ratio: 6.44%
  • Average Volume: 1.18 million shs.
  • Beta: 1.62
  • Short Ratio: 5.13
Frequently Asked Questions for TESARO (NASDAQ:TSRO)

What is TESARO's stock symbol?

TESARO trades on the NASDAQ under the ticker symbol "TSRO."

How were TESARO's earnings last quarter?

TESARO, Inc. (NASDAQ:TSRO) issued its quarterly earnings results on Tuesday, May, 9th. The company reported ($2.55) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($2.26) by $0.29. The firm earned $3.10 million during the quarter, compared to analyst estimates of $3.84 million. TESARO had a negative return on equity of 96.49% and a negative net margin of 910.35%. The business's revenue was up 909.8% on a year-over-year basis. During the same period in the prior year, the firm earned ($2.22) earnings per share. View TESARO's Earnings History.

When will TESARO make its next earnings announcement?

TESARO is scheduled to release their next quarterly earnings announcement on Wednesday, August, 2nd 2017. View Earnings Estimates for TESARO.

Where is TESARO's stock going? Where will TESARO's stock price be in 2017?

21 brokers have issued 1 year price objectives for TESARO's stock. Their forecasts range from $94.00 to $236.00. On average, they expect TESARO's share price to reach $173.52 in the next year. View Analyst Ratings for TESARO.

What are analysts saying about TESARO stock?

Here are some recent quotes from research analysts about TESARO stock:

  • 1. FBR & Co analysts commented, "We received our first data snapshot from the RX-3117 Phase 2a study in advanced muscle invasive bladder cancer at ASCO this weekend with data coming from 10 patients in stage 1 of the study. The study achieved the predefined efficacy criteria (two of ten patients achieving a PFS of at least four months or a partial or complete tumor response), where 22% of patients have experienced PFS for a minimum of six months. One of the two aforementioned patients is still on study, achieving 175 days of stable disease. While only stage 1 of this study, we believe it is important to point out that patients who have reached this stage of disease are usually limited to palliative or best supportive care." (6/5/2017)
  • 2. Cann analysts commented, "On Saturday, June 3, 2017, Tesaro provided a corporate update that described initial data from the TOPACIO trial of niraparib (Zejula) plus Keytruda (pembrolizumab) and results of a phase I trial of TSR-042, and provided an update on the commercial launch of Zejula and its commercial businesses in the US and Europe. The launch is exceeding our expectations, and management reiterated plans to advance Zejula into the front-line ovarian cancer setting and to expand into other tumor types, including non-small cell lung cancer. We are adjusting our Zejula outlook based on the current status of the launch." (6/5/2017)
  • 3. Cowen and Company analysts commented, "TSRO reported 1Q financials, provided a pipeline update and commented on Zejula’s." (5/11/2017)
  • 4. According to Zacks Investment Research, "Tesaro, Inc. is an oncology-focused biopharmaceutical company for cancer patients. The Company's product portfolio consists of Rolapitant, a neurokinin-1 receptor antagonist for the prevention of chemotherapy induced nausea and vomiting, TSR-011, an orally available anaplastic lymphoma kinase inhibitor for the treatment of non-small cell lung cancer and other cancer indications, and Niraparib, an orally active and potent poly (ADP-ribose) polymerase inhibitor for the treatment of patients with solid tumors. Tesaro, Inc. is based in Waltham, Massachusetts. " (3/31/2017)
  • 5. Wedbush analysts commented, "With first-mover advantage in the maintenance setting, a lack of requirement for a diagnostic, as well clinical data that is at least as good as Lynparza in gBRCA patients, we continue to believe that TSRO remains an attractive acquisition candidate." (3/28/2017)

Who are some of TESARO's key competitors?

Who are TESARO's key executives?

TESARO's management team includes the folowing people:

  • David M. Mott, Independent Chairman of the Board
  • Mary Lynne Hedley Ph.D., President, Chief Operating Officer, Director
  • Leon O. Moulder Jr., Chief Executive Officer, Director
  • Timothy R. Pearson, Chief Financial Officer, Executive Vice President
  • Jeffrey H. Hanke Ph.D., Executive Vice President - Research and Development, Chief Scientific Officer
  • Joseph L. Farmer, Senior Vice President, General Counsel, Secretary
  • Grant C. Bogle, Senior Vice President, Chief Commercial Officer
  • Martin H. Huber M.D., Senior Vice President and Chief Medical Officer
  • Lawrence M. Alleva, Independent Director
  • James O. Armitage M.D., Independent Director

Who owns TESARO stock?

TESARO's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include InterWest Venture Management Co (3.75%), Peregrine Capital Management LLC (0.18%), Creative Planning (0.06%), Whittier Trust Co. (0.02%), Jag Capital Management LLC (0.02%) and Capital Impact Advisors LLC (0.02%). Company insiders that own TESARO stock include Arnold L Oronsky, Edward C English, Enterprise Associates 13 L New, Grant C Bogle, James O Armitage, Jeffrey H Hanke, Martin H Jr Huber and Mary Lynne Hedley. View Institutional Ownership Trends for TESARO.

Who sold TESARO stock? Who is selling TESARO stock?

TESARO's stock was sold by a variety of institutional investors in the last quarter, including Jag Capital Management LLC, Peregrine Capital Management LLC, Capital Impact Advisors LLC and CenturyLink Investment Management Co. Company insiders that have sold TESARO stock in the last year include Edward C English, Grant C Bogle, Jeffrey H Hanke, Martin H Jr Huber and Mary Lynne Hedley. View Insider Buying and Selling for TESARO.

Who bought TESARO stock? Who is buying TESARO stock?

TESARO's stock was acquired by a variety of institutional investors in the last quarter, including Creative Planning, Oregon Public Employees Retirement Fund, Mn Services Vermogensbeheer B.V., Bank of Montreal Can, Xact Kapitalforvaltning AB, Capstone Asset Management Co., Private Capital Advisors Inc. and Fox Run Management L.L.C.. Company insiders that have bought TESARO stock in the last two years include Arnold L Oronsky, Enterprise Associates 13 L New and James O Armitage. View Insider Buying and Selling for TESARO.

How do I buy TESARO stock?

Shares of TESARO can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is TESARO's stock price today?

One share of TESARO stock can currently be purchased for approximately $129.87.

MarketBeat Community Rating for TESARO (NASDAQ TSRO)
Community Ranking:  3.3 out of 5 (  )
Outperform Votes:  358 (Vote Outperform)
Underperform Votes:  177 (Vote Underperform)
Total Votes:  535
MarketBeat's community ratings are surveys of what our community members think about TESARO and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for TESARO (NASDAQ:TSRO) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 7 Hold Ratings, 14 Buy Ratings
Consensus Rating:Buy (Score: 2.67)
Consensus Price Target: $173.52 (33.61% upside)

Analysts' Ratings History for TESARO (NASDAQ:TSRO)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
7/19/2017Credit Suisse GroupSet Price TargetBuy$198.00MediumView Rating Details
7/14/2017Janney Montgomery ScottReiterated RatingNeutralLowView Rating Details
7/7/2017GabelliInitiated CoverageBuy$175.00HighView Rating Details
6/20/2017Raymond James Financial, Inc.Reiterated RatingMarket PerformMediumView Rating Details
6/20/2017Leerink SwannLower Price TargetMarket Perform$164.00 -> $143.00HighView Rating Details
6/20/2017Wells Fargo & CompanyReiterated RatingOutperform$236.00HighView Rating Details
6/20/2017Bank of America CorporationReiterated RatingBuy$154.00HighView Rating Details
6/19/2017Cowen and CompanyLower Price TargetMarket Perform$145.00 -> $124.00HighView Rating Details
6/13/2017WedbushReiterated RatingOutperform$160.00 -> $168.00HighView Rating Details
6/6/2017Robert W. BairdReiterated RatingNeutralMediumView Rating Details
6/5/2017FBR & CoLower Price TargetMkt Perform -> Mkt Perform$200.00 -> $195.00HighView Rating Details
6/5/2017CannReiterated RatingBuy$199.00HighView Rating Details
6/4/2017Oppenheimer Holdings, Inc.Set Price TargetBuy$183.00 -> $199.00HighView Rating Details
5/10/2017Jefferies Group LLCReiterated RatingHoldLowView Rating Details
4/22/2017Citigroup Inc.Reiterated RatingBuy$232.00 -> $216.00LowView Rating Details
4/12/2017Piper Jaffray CompaniesInitiated CoverageOverweight -> Overweight$180.00LowView Rating Details
3/28/2017Morgan StanleyBoost Price TargetOverweight$182.00 -> $183.00HighView Rating Details
3/24/2017ArgusInitiated CoverageBuy$210.00HighView Rating Details
2/17/2017Royal Bank Of CanadaBoost Price TargetOutperform$142.00 -> $202.00N/AView Rating Details
2/9/2017SunTrust Banks, Inc.Reiterated RatingBuy -> Average$190.00N/AView Rating Details
11/7/2016Lake Street CapitalReiterated RatingBuy$114.00 -> $150.00N/AView Rating Details
8/5/2016MizuhoLower Price TargetBuy$100.00 -> $94.00N/AView Rating Details
(Data available from 7/24/2015 forward)


Earnings History for TESARO (NASDAQ:TSRO)
Earnings by Quarter for TESARO (NASDAQ:TSRO)
Earnings History by Quarter for TESARO (NASDAQ TSRO)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/2/2017($2.53)N/AView Earnings Details
5/9/2017Q1 2017($2.26)($2.55)$3.84 million$3.10 millionViewListenView Earnings Details
11/3/2016Q3($1.92)($1.98)$4.39 million$3.73 millionViewN/AView Earnings Details
5/5/2016Q1($1.69)($2.22)$2.48 million$0.31 millionViewN/AView Earnings Details
2/25/2016Q4($1.63)($1.89)$3.45 million$0.23 millionViewListenView Earnings Details
10/29/2015Q315($1.52)($1.66)$0.09 millionViewListenView Earnings Details
8/6/2015Q215($1.14)($1.51)ViewListenView Earnings Details
4/30/2015Q115($1.12)($1.30)ViewListenView Earnings Details
2/19/2015Q414($1.03)($1.33)ViewListenView Earnings Details
11/5/2014Q314($1.04)($1.01)ViewN/AView Earnings Details
7/24/2014Q214($0.87)($1.03)ViewN/AView Earnings Details
4/30/2014Q114($1.06)($1.43)ViewN/AView Earnings Details
2/19/2014Q413($0.78)($0.72)ViewN/AView Earnings Details
11/7/2013Q313($0.69)($0.88)ViewN/AView Earnings Details
7/25/2013Q2 2013($0.63)($0.67)ViewN/AView Earnings Details
4/25/2013Q1 2013($0.62)($0.66)ViewN/AView Earnings Details
2/14/2013Q4 2012($0.65)($15.41)ViewN/AView Earnings Details
10/25/2012($0.55)($0.52)ViewN/AView Earnings Details
7/26/2012($0.55)($4.11)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for TESARO (NASDAQ:TSRO)
2017 EPS Consensus Estimate: ($8.55)
2018 EPS Consensus Estimate: ($3.64)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20175($2.39)($1.98)($2.20)
Q2 20176($3.10)($2.15)($2.59)
Q3 20176($2.39)($1.51)($1.97)
Q4 20176($2.27)($1.11)($1.79)
Q1 20182($1.32)($1.27)($1.30)
Q2 20182($1.11)($0.54)($0.83)
Q3 20182($0.84)($0.62)($0.73)
Q4 20182($1.06)($0.52)($0.79)
(Data provided by Zacks Investment Research)


Dividend History for TESARO (NASDAQ:TSRO)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for TESARO (NASDAQ:TSRO)
Insider Ownership Percentage: 34.60%
Insider Trades by Quarter for TESARO (NASDAQ:TSRO)
Institutional Ownership by Quarter for TESARO (NASDAQ:TSRO)
Insider Trades by Quarter for TESARO (NASDAQ:TSRO)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/6/2017Edward C EnglishVPSell8,500$138.65$1,178,525.00View SEC Filing  
4/3/2017Martin H Jr. HuberSVPSell829$153.02$126,853.58View SEC Filing  
3/6/2017Edward C EnglishVPSell10,000$178.06$1,780,600.00View SEC Filing  
3/2/2017Edward C EnglishVPSell229$177.61$40,672.69View SEC Filing  
3/2/2017Grant C. BogleSVPSell1,447$177.61$257,001.67View SEC Filing  
3/2/2017Mary Lynne HedleyCOOSell3,927$177.61$697,474.47View SEC Filing  
1/3/2017Martin H. Jr. HuberSVPSell190$136.26$25,889.40View SEC Filing  
11/2/2016Martin H Jr. HuberSVPSell327$121.29$39,661.83View SEC Filing  
9/22/2016Martin H Jr. HuberSVPSell408$108.12$44,112.96View SEC Filing  
9/8/2016Edward C EnglishVPSell7,000$88.54$619,780.00View SEC Filing  
8/30/2016Jeffrey H HankeVPSell29,166$86.04$2,509,442.64View SEC Filing  
6/30/2016Jeffrey H HankeVPSell12,500$74.35$929,375.00View SEC Filing  
6/10/2016Edward C EnglishVPSell7,000$40.75$285,250.00View SEC Filing  
3/18/2016Arnold L OronskyDirectorBuy142,085$35.19$4,999,971.15View SEC Filing  
3/18/2016Enterprise Associates 13 L NewMajor ShareholderBuy710,429$35.19$24,999,996.51View SEC Filing  
3/10/2016Edward C EnglishVPSell7,000$43.71$305,970.00View SEC Filing  
12/10/2015Edward C. EnglishVPSell17,000$50.19$853,230.00View SEC Filing  
9/8/2015James O ArmitageDirectorBuy500$54.63$27,315.00View SEC Filing  
12/12/2014James O ArmitageDirectorBuy1,000$38.16$38,160.00View SEC Filing  
9/29/2014Lawrence M AllevaDirectorBuy1,100$26.17$28,787.00View SEC Filing  
7/31/2013Lawrence M AllevaDirectorBuy1,449$34.33$49,744.17View SEC Filing  
6/5/2013Peter J BarrisMajor ShareholderSell3,583$39.00$139,737.00View SEC Filing  
4/30/2013Lawrence M AllevaDirectorBuy1,050$28.10$29,505.00View SEC Filing  
11/1/2012Lawrence M AllevaDirectorBuy3,240$15.45$50,058.00View SEC Filing  
8/30/2012Leon O Moulder JrCEOBuy10,000$11.69$116,900.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for TESARO (NASDAQ:TSRO)
Latest Headlines for TESARO (NASDAQ:TSRO)
americanbankingnews.com logoTESARO, Inc. (TSRO) Given a $198.00 Price Target at Credit Suisse Group
www.americanbankingnews.com - July 23 at 3:04 PM
americanbankingnews.com logoZacks: Brokerages Expect TESARO, Inc. (TSRO) Will Announce Quarterly Sales of $17.22 Million
www.americanbankingnews.com - July 20 at 3:58 PM
americanbankingnews.com logo Brokerages Expect TESARO, Inc. (TSRO) to Post -$2.51 EPS
www.americanbankingnews.com - July 18 at 11:54 AM
americanbankingnews.com logoSunTrust Banks Weighs in on TESARO, Inc.'s FY2018 Earnings (NASDAQ:TSRO)
www.americanbankingnews.com - July 17 at 10:57 AM
americanbankingnews.com logoTESARO, Inc. (NASDAQ:TSRO) Given "Neutral" Rating at Janney Montgomery Scott
www.americanbankingnews.com - July 14 at 7:58 PM
benzinga.com logoWall Street's M&A Chatter From July 13: Tesaro, Time, Frontier Communications, First Citizens BancShares, Brink's ... - Benzinga
www.benzinga.com - July 14 at 4:22 PM
investorplace.com logoTESARO Inc (TSRO) Shares Fall as Company Struggles to Find Buyer - Investorplace.com
investorplace.com - July 14 at 4:22 PM
rttnews.com logoTesaro Inc. (TSRO) Dropped On Reports That Sale Seems Unlikely
www.rttnews.com - July 14 at 9:27 AM
feeds.benzinga.com logoWall Street's M&A Chatter From July 13: Tesaro, Time, Frontier Communications, First Citizens BancShares, Brink's-Maco Transportadora
feeds.benzinga.com - July 14 at 7:29 AM
investorplace.com logoTESARO Inc (TSRO) Shares Fall as Company Struggles to Find Buyer
investorplace.com - July 13 at 1:28 PM
seekingalpha.com logoTesaro Shows Good Potential With Major Approvals This Year
seekingalpha.com - July 13 at 10:48 AM
nasdaq.com logoTesaro Inc. (TSRO) Is Sinking On Reports That Sale Is Unlikely
www.nasdaq.com - July 13 at 10:48 AM
cnbc.com logoSale process for biotech Tesaro seen unlikely to result in deal
www.cnbc.com - July 13 at 10:24 AM
americanbankingnews.com logoTESARO, Inc. (NASDAQ:TSRO) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - July 11 at 8:26 PM
barrons.com logoTesaro: Why Gabelli Sees 20%+ Upside - Barron's
www.barrons.com - July 8 at 2:54 PM
americanbankingnews.com logoTESARO, Inc. (TSRO) Now Covered by Gabelli
www.americanbankingnews.com - July 7 at 10:18 AM
americanbankingnews.com logoBidaskClub Downgrades TESARO, Inc. (NASDAQ:TSRO) to Sell
www.americanbankingnews.com - June 30 at 4:04 PM
nasdaq.com logoTESARO Joins OCRFA as Presenting Sponsor of the 2017 Ovarian Cancer National Conference - Nasdaq
www.nasdaq.com - June 29 at 8:42 PM
finance.yahoo.com logoTESARO Joins OCRFA as Presenting Sponsor of the 2017 Ovarian Cancer National Conference
finance.yahoo.com - June 29 at 3:41 PM
globenewswire.com logoTESARO Announces Lonnie Moulder and Mary Lynne Hedley Named EY Entrepreneurs of the Year® New England - GlobeNewswire (press release)
globenewswire.com - June 29 at 7:33 AM
americanbankingnews.com logo Analysts Anticipate TESARO, Inc. (TSRO) Will Announce Quarterly Sales of $17.22 Million
www.americanbankingnews.com - June 23 at 1:00 PM
americanbankingnews.com logoFY2018 EPS Estimates for TESARO, Inc. Reduced by Leerink Swann (TSRO)
www.americanbankingnews.com - June 22 at 1:04 PM
americanbankingnews.com logoZacks: Analysts Expect TESARO, Inc. (TSRO) to Announce -$2.55 Earnings Per Share
www.americanbankingnews.com - June 22 at 12:16 AM
americanbankingnews.com logoTESARO, Inc. to Post Q3 2017 Earnings of ($1.64) Per Share, Wedbush Forecasts (TSRO)
www.americanbankingnews.com - June 21 at 8:36 AM
americanbankingnews.com logoTESARO, Inc. (TSRO) Receives "Market Perform" Rating from Raymond James Financial, Inc.
www.americanbankingnews.com - June 20 at 2:56 PM
americanbankingnews.com logoTESARO, Inc. (TSRO) PT Lowered to $143.00 at Leerink Swann
www.americanbankingnews.com - June 20 at 8:10 AM
americanbankingnews.com logoTESARO, Inc. (TSRO) Price Target Cut to $120.00 by Analysts at Janney Montgomery Scott
www.americanbankingnews.com - June 20 at 7:58 AM
americanbankingnews.com logoTESARO, Inc. (TSRO) Rating Reiterated by Cowen and Company
www.americanbankingnews.com - June 19 at 1:32 PM
feeds.benzinga.com logoTesaro Comes Roaring Back From Much Lower Open
feeds.benzinga.com - June 19 at 12:00 PM
americanbankingnews.com logoTESARO, Inc. (TSRO) Receives Consensus Rating of "Buy" from Brokerages
www.americanbankingnews.com - June 16 at 6:32 PM
finance.yahoo.com logoETFs with exposure to TESARO, Inc. : June 15, 2017
finance.yahoo.com - June 15 at 3:37 PM
americanbankingnews.com logoLeerink Swann Comments on TESARO, Inc.'s FY2018 Earnings (TSRO)
www.americanbankingnews.com - June 15 at 12:52 PM
finance.yahoo.com logoTESARO, Inc. breached its 50 day moving average in a Bullish Manner : TSRO-US : June 14, 2017
finance.yahoo.com - June 14 at 8:58 AM
fool.com logoWill Tesaro Be the Focus of the Next Biotech Bidding War?
www.fool.com - June 13 at 5:22 PM
finance.yahoo.com logoToday's Research Reports on Stocks to Watch: Gilead Sciences and Tesaro
finance.yahoo.com - June 13 at 9:23 AM
americanbankingnews.com logoTESARO, Inc. (TSRO) Rating Reiterated by Wedbush
www.americanbankingnews.com - June 13 at 8:28 AM
feeds.benzinga.com logoWall Street's M&A Chatter From June 12: Neuroderm, Penn Virginia, Tesaro, Synaptics-Conexant
feeds.benzinga.com - June 13 at 7:23 AM
americanbankingnews.com logoTESARO's (TSRO) "Outperform" Rating Reaffirmed at Wells Fargo & Company
www.americanbankingnews.com - June 12 at 9:54 AM
americanbankingnews.com logoTESARO, Inc. (TSRO) Given a $145.00 Price Target by Cowen and Company Analysts
www.americanbankingnews.com - June 11 at 10:52 PM
americanbankingnews.com logoTESARO, Inc. (TSRO) PT Set at $139.00 by Janney Montgomery Scott
www.americanbankingnews.com - June 11 at 10:52 PM
americanbankingnews.com logoTESARO Inc (TSRO) Given "Neutral" Rating at Robert W. Baird
www.americanbankingnews.com - June 11 at 12:46 PM
benzinga.com logoTesaro Volatile After Johnson & Johnson Suspends Enrollment In Prostrate Cancer Trial - Benzinga
www.benzinga.com - June 10 at 9:17 AM
americanbankingnews.com logoInsider Selling: TESARO Inc (TSRO) VP Sells 8,500 Shares of Stock
www.americanbankingnews.com - June 8 at 7:12 PM
finance.yahoo.com logoTESARO Announces Participation at Goldman Sachs 38th Annual Global Healthcare Conference
finance.yahoo.com - June 8 at 1:30 AM
americanbankingnews.com logoTESARO Inc (TSRO) to Post Q2 2017 Earnings of ($2.28) Per Share, FBR & Co Forecasts
www.americanbankingnews.com - June 7 at 7:52 AM
americanbankingnews.com logoQ2 2017 EPS Estimates for TESARO Inc (TSRO) Raised by Analyst
www.americanbankingnews.com - June 7 at 7:50 AM
finance.yahoo.com logoTesaro: What's Tearing At The Stock?
finance.yahoo.com - June 7 at 12:01 AM
finance.yahoo.com logoETFs with exposure to TESARO, Inc. : June 5, 2017
finance.yahoo.com - June 7 at 12:01 AM
americanbankingnews.com logoFY2019 Earnings Estimate for TESARO Inc (TSRO) Issued By FBR & Co
www.americanbankingnews.com - June 6 at 1:24 PM
americanbankingnews.com logoTESARO Inc (TSRO) to Post FY2019 Earnings of $2.08 Per Share, Oppenheimer Holdings Forecasts
www.americanbankingnews.com - June 6 at 1:00 PM



TESARO (TSRO) Chart for Monday, July, 24, 2017

This page was last updated on 7/24/2017 by MarketBeat.com Staff